Metropolis Healthcare Limited has announced the launch of its Centre of Genomics, a significant expansion of its capabilities in advanced genomics, molecular diagnostics, precision medicine, and genomic research. This initiative aims to deliver clinically actionable genomic insights across various high-impact clinical specialties, including oncology, reproductive health, neurology, transplant immunology, and rare diseases.

The Centre of Genomics is built upon the integration of Metropolis' Global Reference Laboratory in Mumbai and the specialized genomics laboratory of Core Diagnostics in the Delhi NCR region. These facilities are CAP-accredited national referral laboratories for genomics, forming the core of the new centre. This integrated model combines a broad portfolio of NGS-based assays, robust bioinformatics and interpretation capabilities, and deep scientific and clinical expertise.

To strengthen its technological backbone, Metropolis has deployed Illumina’s NovaSeq™ X Series for research purposes. This advanced sequencing system offers high throughput and accuracy, capable of generating over 20,000 whole genomes per year. The Centre of Genomics also leverages existing multi-platform NGS infrastructure across Metropolis' key hubs and multidisciplinary teams, including molecular pathologists, genomic scientists, bioinformaticians, and genetic counselors.

Ms. Ameera Shah, Promoter and Executive Chairperson, stated that the Centre of Genomics represents an inflection point for diagnostics in India, moving beyond disease detection to risk prediction and therapy personalization. She emphasized the importance of rigorous validation, deep expertise, quality assurance, and clinical responsibility. Dr. Kirti Chadha, Chief Scientific and Innovation Officer, highlighted that the Centre is designed to translate advanced genomic science into actionable clinical decision-making, with a plan to expand the genomic portfolio to over 500 assays within the next two to three years.

Illumina expressed its commitment to making advanced sequencing technologies more accessible in India, with its Country Head for India noting Metropolis Healthcare's leverage of the NovaSeq™ X Series for transformative research. The Centre of Genomics is also positioned as a platform for continuous test development, AI-enabled analytics, and digital integration, aiming to serve as a strategic partner for global research, companion diagnostics, and precision-led drug development.